WASPSTINGS · Unravelling the mechanism for development of WASP-associated primary immunodeficiency
FP7 — People (Marie Curie Actions)
- Duration
- 2010-04-01 → 2014-03-31
- EU contribution
- €100,000
- Participants
- 1
- Scheme
- MC-IRG
Lines connect the coordinator with its partners.
Results in brief
Unravelling the mechanism for development of WASP-associated primary immunodeficiency
Westerberg Laboratory Lab web page: http://ki.se/en/mtc/lisa-westerberg-group I started the Immunodeficiency group at Karolinska Institutet in 2009 after receiving a VR Assistant Professor grant and after completing 5 years of postdoctoral training at Harvard Medical School. Recent data from my laboratory challenge the concept that WASP deficiency leads to an immune-compromised setting. Our data show that B cells devoid of WASP fail to undergo proper affinity maturation in germinal centers. Instead, we found an increased extrafollicular response in WASP-deficient mice with expansion of B cells that recognize autoantigens (Dahlberg et al, submitted). Moreover, we found that skin pathology is associated with hyperactive CD8+ T cells and increased cross-presentation by dendritic cells (Baptista et al, Immunity under review). Together, these data has led us to postulate the working hypothesis that WASP-associated immunodeficiencies induce a breach in tolerance by activation of the ‘wrong’ cells at incorrect sites. We reason and will test that this altered response is due to strong compensatory mechanisms in cell signaling so that when one molecule is missing (for example WASP) - another pathway is activated that regulate a different cellular response. I believe the next frontier is to understand the cross-talk between different members in the WASP family signalling pathway and their role inside the nucleus. I have during the first 5 years at KI created a large platform of gene-targeted mice in which we are studying WASp family members and their interaction partners in their natural environment of the immune system. We have developed new molecular tools and designed new gene therapy approaches and many of these strains are so far unpublished. The long-term vision with this approach is to bridge the gap between immunology and cell biology and to work close to clinicians in already established collaborations. I expect that my laboratory has contributed with the following groundbreaking findings in 6 years and of interest for the broad scientific community: Cell biology – Identification of the function of actin regulators such as WASp in the cytoplasm for vesicle dynamics and cellular stress and in the nucleus for chromatin remodelling and maintenance of genetic stability Immunology – Identification of the role of WASp family members and their molecular regulation in leukocyte biology Preclinical and clinical trials – Showing proof-of-concept using new Gene Therapy approaches with small interfering RNAs in mice and thereafter translating to clinic as new therapeutic approaches for diseases caused by dominant active proteins New tools to investigate the immune system – Development of novel gene-targeted models using molecular biology approaches in the forefront of biomedical research My strategy on the path to becoming a principal investigator has been to: (1) complete research from my postdoctoral work (see Publication list 2 and 5), (2) set up a large methodological platform (Figure 2), and (3) to secure ample funding. In 2012, I became a Ragnar Söderberg fellow in Medicine (SEK 8.000.000) and the Swedish research Council granted me SEK 10.000.000 for highly ranked ERC-StG2012. In 2013, I was recruited to Department of Microbiology, Tumor, and Cell biology where I received a starting grant to design my laboratory exactly to meet our needs. Since I joined Karolinska Institutet in 2009 I have published 5 papers (PNAS 2009, J Exp Med 2010, Blood 2012a and Blood 2012b, PLoS Biology 2013) and 1 commentary (Blood) and my group has 3 more papers in the pipeline where I am senior author and 4 as co-authors. I am actively solidifying my current international collaborations by coordinating the ‘WASPSTINGS’ network funded by STINT and I am organizing a large scientific meeting (see immunology2014.se).
Data: CORDIS, © European Union
Project objective
Two severe primary immunodeficiencies; Wiskott-Aldrich syndrome (WAS) and X-linked neutropenia (XLN), are caused by mutations in the same gene encoding the WAS protein (WASP). WASP is a hematopoietic cell-specific cytoskeletal regulator that coordinates receptor signalling to changes in the actin cytokeleton, thereby altering migratory, adhesive, phagocytic, and signalling responses. WAS is caused by loss-of-function mutations in WASP. WAS patients and WASP-deficient mice are immuno-compromised, fail to respond to foreign pathogens, and are prone to develop eczema and autoimmune disease. In contrast, XLN is caused by gain-of-function mutations that lead to a constitutively-active WASP. XLN patients suffer from severe congenital neutropenia. It remains unknown how different mutations in WASP can induce vastly diverse clinical phenotypes. I hypothesize that similar to WASP deficiency, XLN-WASP mutations may affect hematopoietic cells broadly. Moreover, I hypothesize that altered tolerance to self leads to induction of eczema and autoimmunity in WAS patients and WASP-deficient mice. I propose; AIM 1: To reveal the underlying cause for development of XLN by usage of a novel mouse model that I generated during my postdoctoral work. We will determine how XLN-WASP influences the immune response, induces neutropenia, and tumour transformation. AIM 2: To investigate how WAS patients and WASP-deficient mice that fail to respond to foreign pathogens still react vigorously to self and develop eczema and autoimmunity. This project is carried out as a multidisciplinary and translational collaboration together with my postdoctoral mentors in the USA, and researchers in Italy, England, and Sweden. The long-term goal with the project is to increase the mobility of European researchers and the European excellence by defining future targets for therapeutic intervention and to understand the requirement of WASP and the actin cytoskeleton for correct function of hematopoietic cells.
Original text from CORDIS.
Participants
- KAROLINSKA INSTITUTET · STOCKHOLMCoordinatorSweden
Links
Data: CORDIS, © European Union
